Home › Castration-Resistant Prostatic Cancer › Massachusetts
Castration-Resistant Prostatic Cancer clinical trials in Massachusetts
5 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Massachusetts General, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Dana Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07719361A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT06067841From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.